NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.64 (-0.66%)

Growth Price

Overvalued by 29.42%

Stability Price

Overvalued by 74.32%

Company Metrics

  • 22.26 P/E
  • 3.92 P/S
  • 3.28 P/B
  • 4.352 EPS
  • 13.46% Cash ROIC
  • 0.35 Cash Ratio
  • 2.719 / 2.81% Dividend
  • 1.61M Avg. Vol.
  • 232.8B Market Cap.

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Novartis AG (ADR) (NVS)'s Cosentyx Gets Clearance In Europe
InvestCorrectly - Jan 20, 2015
Novartis AG (ADR) (NYSE:NVS)'s Cosentyx™ gets the European Commission approval to be the first-line treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy.
Stock Watch: Novartis AG (ADR) (NYSE:NVS), MGIC Investment Corp. (NYSE ... - Realist Investor
Novartis Gets European Approval For Potential Blockbuster Cosentyx - Bidness ETC
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Markets Wired - Jan 21, 2015
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
Brokerage Firm Price Target on Novartis AG (ADR) - Stafford Daily
Novartis AG (ADR) Investors Book Profit on Strength - Bar and Graph Report
First Call Rating Update on Novartis AG (ADR)
Stafford Daily - 5 hours ago
Novartis AG (ADR) (NYSE:NVS) has received a Buy rating from First Call in their declaration. The rating agency has disclosed the information in the equity research recommendation.
Investors Book Profit on the Price Strength of Novartis AG (ADR) - Bar and Graph Report
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
NASDAQ - Jul 25, 2014
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Options Check-Up: Bristol-Myers Squibb, Merck & Co., and Novartis AG
Schaeffers Research (blog) - Jan 23, 2015
Among the stocks attracting attention from options traders lately are pharmaceutical firms Bristol-Myers Squibb Co (NYSE:BMY), Merck & Co.
Novartis AG (ADR) Analyst Rating Update
Stafford Daily - Jan 12, 2015
Analysts at Zacks have given a Neutral rating on Novartis AG (ADR) (NYSE:NVS) with a rank of 3. The counter has received an average rating of 2 from 8 brokerage firms.
Here's Why Novartis AG (NVS) Stock Could Fall Today
Bidness ETC - Dec 1, 2014
Novartis AG (ADR) (NYSE:NVS) announced early Monday morning that its drug Gilenya failed to meet its primary endpoint in a Phase III study, called INFORMS, designed to measure the efficacy of the drug in treating primary-progressive multiple sclerosis ...
Novartis' Gilenya Fails To Treat Progressive MS NVS BIIB - Investor's Business Daily
Novartis AG (ADR) Receives Analyst Recommendation
Stafford Daily - Jan 7, 2015
Cowen upgraded Novartis to Outperform based on promising pipeline candidates, divestitures of under-performing businesses, clarified generic risks, and attractive valuation.
Novartis AG Raised to Outperform at Cowen and Company (NVS) - sleekmoney
Investor Watch: Novartis AG (ADR) (NYSE:NVS), Whiting Petroleum Corp (NYSE ...
Stafford Daily - Dec 3, 2014
Novartis AG (ADR) (NYSE:NVS) was upgraded to a equal weight rating by analysts at Morgan Stanley. Analysts at Morgan Stanley believe that the company provides prime value to investors going forward and the growth trajectory for the company looks intact ...
Novartis AG Rating Increased to Equal Weight at Morgan Stanley (NVS) - Mideast Time
GSK Shareholders In Favor Of Novartis (NVS) Deal
Bidness ETC - Dec 19, 2014
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced that its shareholders voted in “overwhelming majority” in favor of the company's multi-billion swapping deal with Novartis AG (ADR) (NYSE:NVS) in the annual shareholder meeting held on December 18.